All
- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
language
23
2018
-
08
The "Semi-synthetic Artemisinin" project of Chongqing Medical and Engineering Institute has received funding from the Gates Foundation.
Source:
The "semi-synthetic artemisinin" project of Chongqing Medical Engineering Institute received funding from the Gates Foundation.
In July 2018, the R&D platform of Fosun Pharma, Chongqing Medical Industry Research Institute Co., Ltd. (hereinafter referred to as "Chongqing Medical Engineering Institute"), reached a cooperation with the non-profit organization Bill and Melinda Gates Foundation (hereinafter referred to as "Gates Foundation"). The "semi-synthetic artemisinin" project researched by Chongqing Medical Engineering Institute received a grant of $450,000 from the Gates Foundation, dedicated to the research of large-scale production processes for semi-synthetic artemisinin.
Malaria is one of the leading fatal infectious diseases in the world. According to the 2017 WHO World Malaria Report, by the end of 2016, about half of the population in 91 countries worldwide was still at risk of malaria, with a total of 216 million malaria cases reported and 445,000 deaths. As a new type of effective anti-malarial drug, artemisinin-based combination therapies have been adopted as the first-line treatment for malaria in 80 countries.
According to Synbiowatch, the annual production of artemisinin raw materials worldwide is 200 tons, of which 80% comes from natural plant extraction and production in China. Currently, artemisinin faces production limitations due to factors such as price volatility, complex extraction processes, and environmental and ecological protection. Achieving chemical synthesis and industrial production of artemisinin has always been a major challenge for the global pharmaceutical industry.
The "semi-synthetic artemisinin" project of Chongqing Medical Engineering Institute adopts artificial synthesis methods and has achieved scale-up verification at 300L. In the future, Chongqing Medical Engineering Institute will use continuous flow reaction technology for the most critical reaction steps, improving process efficiency and reducing costs to achieve industrial production of the project.
In the field of anti-malarial drugs, Fosun Pharma is a global leader in the R&D and manufacturing of anti-malarial drugs. Currently, the global sales of the innovative injectable artemether developed by Fosun Pharma, which has completely independent intellectual property rights, have exceeded 100 million doses, helping over 20 million severe malaria patients worldwide regain their health, most of whom are African children under the age of five.
Company Profile
Chongqing Medical Engineering Institute is a comprehensive research and development unit and industrialization base mainly engaged in the research and development of chemical synthetic drugs and traditional Chinese and Western medicine preparations, jointly established by Fosun Pharma and Chongqing Pharmaceutical (Group) Co., Ltd. In the past two decades, it has completed more than 200 national key projects such as the "Seventh Five-Year Plan", "Eighth Five-Year Plan", "Eleventh Five-Year Plan", "Twelfth Five-Year Plan", "863" program projects, and key projects of Chongqing City, and has won more than 30 national and provincial-level scientific and technological achievement awards. It has been recognized as a national high-tech enterprise, an innovative enterprise in Chongqing, and a research center for chemical pharmaceutical engineering technology in Chongqing.
Key words:
In the future digital transformation of the pharmaceutical industry, how should pharmaceutical companies position themselves
2021-04-13
The current status of the development of the pharmaceutical industry in China in 2020.
2019 was an important year for the transformation and key upgrade of the pharmaceutical industry in our country.
2021-04-13
Progress has been made in the research of nano-medicines for pancreatic cancer.
Pancreatic cancer has a high mortality rate, and its fundamental reason for being difficult to treat lies in the fact
2021-04-13
Nanfang Daily News - On April 9, the fifth Cloud Cheng Tian Yu Food and Drug Review and Certification
2021-04-13
Contact
565 Tu Shan Road, Nan 'an District, Chongqing
Tel: 86-023-62505956
E-mail: cpri@cpri.com.cn
Tel: 86-023-62505956
E-mail: cpri@cpri.com.cn
Scan mobile websites
